reports
Curaleaf Holdings Inc: 1 director
A director at Curaleaf Holdings Inc sold 160,374 shares at 0.000CAD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Compagnie de l'Odet : Mise en ligne du rapport financier annuel 2023
Compagnie de l'Odet : Mise en ligne du rapport financier annuel 2023 24 avril 2024 COMPAGNIE DE L’ODET Mise en ligne du rapport financier annuel 2023 Compagnie de l’Odet annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier annuel portant sur l’exercice 2023. Le rapport financier annuel peut être consulté sur le site internet de la société à l’adresse (Investisseurs/Informations réglementées/Rapport financier annuel). Ce rapport financier annuel inclut notamment le rapport sur le gouvernement d’entreprise joint au rapp...
HiDeep Inc: 1 director
A director at HiDeep Inc bought 419,267 shares at 1,180.651KRW and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Kinergy Advancement Berhad: 1 director
A director at Kinergy Advancement Berhad bought 4,255,700 shares at 0.345MYR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- Emna Ben Bdira
- Maxime Kogge
SSAB : Sound Q1 results thanks to Special Steels and Europe, decent Q2...
>Q1 a strong beat on Europe and Special Steels, Americas more underwhelming - SSAB delivered better-than-expected Q1 results with EBITDA at SEK 4.1bn, 18% > consensus and 26% > ODDO BHF. The beat was essentially driven by the Special Steels division which achieved SEK 2.1bn of EBITDA, 45% > consensus on very sound volume growth (+17% q-o-q) as good demand in material handling offset weakness in construction. Europe also outperformed with EBITDA at SEK 0.6bn, 44% > con...
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 An...
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting...
EQS-News: TVM Capital Healthcare Announces EUR 16 Million Investment i...
EQS-News: neurocare group AG / Key word(s): Investment TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare 24.04.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare neurocare is revolutionizing mental health care by providing innovative methods and tools based on neurostimulation and other technologies to help clinicians deliver personalized treatments with sustainable clinical outcomes for patients. The investment will enable the comp...
LUX And MX Player Partner To Challenge Outdated Sexist Scenes With An ...
EQS Newswire / 24/04/2024 / 10:00 CET/CEST Empowering Women By Disrupting Sexist Narratives in the Indian Film Industry: LUX Launches 'The End' CampaignSINGAPORE - - 24 April 2024 - VML Singapore and LUX, the global beauty brand under Unilever, has partnered with MX Player, a leading OTT platform, to launch a fresh new campaign that tackles a deeply ingrained issue in Indian cinema: the normalisation of sexism. The campaign titled 'The End', shines a light on how classic Indian films, while undeniably popular on streaming platforms, often portray outdated narratives where men disregard ...
- Daniel Grossjohann
- Dr. Roger Becker
Zusätzliche € 7 Mio. Auftragseingang sind eine Folge des SMG-Großproje...
MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Das Mitte April vermeldete SMG-Großprojekt (SMG = “Sprechsätze mit Gehörschutz“) bringt nun - wie CeoTronics (ISIN DE0005407407, B...
ARKEMA : MISE À DISPOSITION DES INFORMATIONS RELATIVES À L’ASSEMBLÉE G...
COLOMBES, France--(BUSINESS WIRE)-- Regulatory News: Les actionnaires de la société Arkema (Paris:AKE) sont invités à participer à l’Assemblée générale mixte qui se tiendra le mercredi 15 mai 2024 à 10 heures au Théâtre des Sablons, 70 avenue du Roule, 92200 Neuilly-sur-Seine. Les informations visées à l’article R. 22-10-23 du Code de commerce incluant l’avis de réunion publié au Bulletin des Annonces Légales Obligatoires (BALO) le 27 mars 2024, la brochure de convocation et les modalités de participation et de vote à cette Assemblée générale sont disponibles sur le site internet d’Arkema ...
Sandvik AB: 1 director
A director at Sandvik AB bought 1,500,000 shares at 228.810SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Brickworks Limited: 1 director
A director at Brickworks Limited sold after exercising options/sold 100,000 shares at 27.130AUD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
Greenyield Berhad: 1 director
A director at Greenyield Berhad sold 12,000,000 shares at 0.200MYR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Leader Steel Holdings Bhd: 1 director
A director at Leader Steel Holdings Bhd bought 2,950,600 shares at 0.492MYR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Alvotech Announces Topline Results from a Confirmatory Clinical Study ...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech com...
Alvotech Announces Topline Results from a Confirmatory Clinical Study ...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture o...
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir s...
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab) Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega liðagigtAlvotech er fyrsta fyrirtækið sem birt hefur jákvæðar niðurstöður úr klínískri rannsókn á sjúklingum sem ber saman líftæknilyfjahliðstæðu og Simponi eða Simponi Aria Alvotech (NASDAQ: ALVO) kynnti í dag jákvæða niðurstöðu klínískrar rannsóknar...
Moody's Ratings assigns Aa2 rating to Korea Expressway Corp's USD MTN ...
MOODY'S INVESTORS SERVICE 1Moody's Ratings, 한국도로공사의 미 달러화 표시 MTN 발행에 'Aa2' 신용등급 부여 2024 년 4 월 24 일、 홍콩 、 한국어 보도자료는 영문 보도자료의 번역본입니다. 한국어와 영문 보도자료 간에 상이한 점이 있을 경우 영어 원문이 우선합니다.Moody’s Ratings(이하 ‘무디스’)는 한국도로공사(Aa2 안정적)가 발행할 예정인 미달러화 표시 선순위 무담보 채권에 'Aa2' 신용등급을 부여하였다.전망은 ‘안정적’이다.동 채권은 한국도로공사의 기존 35억 달러 ...
Moody's Ratings assigns Aa2 rating to Korea Expressway Corp's USD MTN ...
Moody's Ratings (Moody's) has assigned a rating of Aa2 to the proposed senior unsecured US dollar notes to be issued by Korea Expressway Corporation (KEC, Aa2 stable). The rating outlook is stable. The notes will be issued under KEC's existing USD3.5 billion global medium-term note (MTN) program...
- Jean-François Granjon
Nexans : Excellent start to the year and full-year guidance confirmed
>Q1 revenues in line with our expectations - Nexans reported standard revenues (on constant non-ferrous metal prices) of € 1.692bn (€ 1.6932bn est.) vs € 1.674bn up 1% and +2.8% in organic terms (+1.2% est.). Excluding the metallurgy business, which is deliberately lower, organic growth came to 4.7% despite fairly adverse comps (+6.5%). For the electrification business (60.5% of the total), revenues came to € 1.025bn, up by 6.7% in organic terms (+6.2% est.).§h...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.